These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28781990)

  • 21. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of omics-based human liver platforms for investigating the mechanism of drug-induced hepatotoxicity in vitro.
    Jiang J; Pieterman CD; Ertaylan G; Peeters RLM; de Kok TMCM
    Arch Toxicol; 2019 Nov; 93(11):3067-3098. PubMed ID: 31586243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circadian hormone control in a human-on-a-chip: In vitro biology's ignored component?
    Cyr KJ; Avaldi OM; Wikswo JP
    Exp Biol Med (Maywood); 2017 Nov; 242(17):1714-1731. PubMed ID: 29065796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective.
    Ainslie GR; Davis M; Ewart L; Lieberman LA; Rowlands DJ; Thorley AJ; Yoder G; Ryan AM
    Lab Chip; 2019 Sep; 19(19):3152-3161. PubMed ID: 31469131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of entacapone and tolcapone on mitochondrial membrane potential.
    Haasio K; Koponen A; Penttilä KE; Nissinen E
    Eur J Pharmacol; 2002 Oct; 453(1):21-6. PubMed ID: 12393055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
    Grünig D; Felser A; Bouitbir J; Krähenbühl S
    Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
    Borges N
    Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
    Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
    Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
    J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of an Integrated Human Multiorgan Microphysiological System for Combined Tolcapone Metabolism and Brain Metabolomics.
    Wang X; Cirit M; Wishnok JS; Griffith LG; Tannenbaum SR
    Anal Chem; 2019 Jul; 91(13):8667-8675. PubMed ID: 31181164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies.
    Edington CD; Chen WLK; Geishecker E; Kassis T; Soenksen LR; Bhushan BM; Freake D; Kirschner J; Maass C; Tsamandouras N; Valdez J; Cook CD; Parent T; Snyder S; Yu J; Suter E; Shockley M; Velazquez J; Velazquez JJ; Stockdale L; Papps JP; Lee I; Vann N; Gamboa M; LaBarge ME; Zhong Z; Wang X; Boyer LA; Lauffenburger DA; Carrier RL; Communal C; Tannenbaum SR; Stokes CL; Hughes DJ; Rohatgi G; Trumper DL; Cirit M; Griffith LG
    Sci Rep; 2018 Mar; 8(1):4530. PubMed ID: 29540740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human organotypic bioconstructs from organ-on-chip devices for human-predictive biological insights on drug candidates.
    Cavero I; Guillon JM; Holzgrefe HH
    Expert Opin Drug Saf; 2019 Aug; 18(8):651-677. PubMed ID: 31268355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro models to study hepatotoxicity.
    Groneberg DA; Grosse-Siestrup C; Fischer A
    Toxicol Pathol; 2002; 30(3):394-9. PubMed ID: 12051557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations.
    Wang X; Kopec AK; Collinge M; David R; Grant C; Hardwick RN; Navratil A; Patel N; Rowan W; Marshall N
    ALTEX; 2022 Aug; 40(2):314–336. PubMed ID: 36044561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies.
    Tsamandouras N; Chen WLK; Edington CD; Stokes CL; Griffith LG; Cirit M
    AAPS J; 2017 Sep; 19(5):1499-1512. PubMed ID: 28752430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Benabou R; Waters C
    Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.